Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution?

MSN
2025.11.18 11:30
portai
I'm PortAI, I can summarize articles.

AbCellera Biologics Inc. (NASDAQ:ABCL) is transitioning from a partnership model to developing its own clinical assets. This strategic shift was reaffirmed at the Stifel 2025 Healthcare Conference on November 13. Wall Street maintains a buy stance on the stock amid this business model evolution.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.